The NSCLC Content Hub Channel

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

Complementary Blood and Tissue Molecular Testing for Newly Diagnosed NSCLC

Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is essential to effective targeted therapies, Dr. Socinski suggests complementary testing of both tissue and blood samples for the most comprehensive approach.

Learn more by clicking here.

More in NSCLC Content Hub

► 1:20

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

NSCLC Content Hub

Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center - James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine...

► 3:51

Importance of Biomarker Testing for RET in Non Small Cell Lung Cancer

NSCLC Content Hub

Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations...

► 1:01

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

NSCLC Content Hub

Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow recommends next-generation...

► 1:38

Molecular Testing Used for Patients With Non-Small Cell Lung Cancer

NSCLC Content Hub

Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous non-small cell...